Search results for: back pain

U.S. Senators Worry about Rush over Healthcare Bill ahead of Release

Susan Cornwell | June 21, 2017

WASHINGTON (Reuters)—U.S. senators expressed concern on Wednesday about a plan to overhaul the U.S. healthcare system, fearing a rush to consider the major legislation as Republican leaders prepare to unveil it. The healthcare bill will be released to the Republican Senate Conference on Thursday at 9:30 a.m. EDT (1330 GMT) and posted online, Senators John…

The Walk from the Waiting Room

Carina Stanton | June 16, 2017

For a rheumatology practice, rooming time can be leveraged to improve efficiency and patient care. Christie Bartels, MD, MS, and colleagues have studied this time frame and developed data-based tips and tools to decrease variation among staff and streamline practices…

FDA Responds to New Drug Application for Baricitinib

Michele B. Kaufman, PharmD, BCGP | June 15, 2017

Oxycodone Tablets Submitted to FDA Filings for oxycodone tablets (Oxaydo) in both 10 and 15 mg doses have been accepted by the U.S. Food and Drug Administration (FDA).1 The submission is based on a pharmacokinetic study demonstrating bioequivalence to the reference drug, oxycodone hydrochloride (Roxicodone) tablets at a 15 mg dose. The product is an…

International Task Force Recommends Intra-articular Hyaluronic Acid for Knee OA

Kathy Holliman | June 15, 2017

An international task force convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) recommends systematic repeated intra-articular hyaluronic acid (HA) injections as second-line treatment for patients with knee osteoarthritis (OA). This is the first time a group of experts has made this recommendation, which is directed toward treatment of…

Rheumatology Online Educational Courses Among Key ARHP Pillars

Paul M. Adam, MSW, & Afton L. Hassett, PsyD | June 15, 2017

Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. The ARHP Online Education Portfolio continues to evolve and grow. The Advanced Rheumatology Course (ARC) and the Fundamentals of Rheumatology Course (FRC)…

The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

Simon M. Helfgott, MD | June 15, 2017

Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Susan Bernstein | June 14, 2017

While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

Rheumatologist Dr. Sandra Pagnussat Recalls Journey from Patient to Physician

Linda Childers | June 14, 2017

When she was in elementary school, Sandra Pagnussat, MD, began experiencing unrelenting pain and stiffness, first in her pinky and then in her other fingers. Her pediatrician diagnosed her with polyarticular juvenile idiopathic arthritis (JIA). In high school, Sandra decided to pursue a career in medicine and began taking advanced placement classes in biology and chemistry….

FDA Asks Endo to Withdraw Opana ER Opioid

Reuters Staff | June 10, 2017

(Reuters)—The U.S. Food and Drug Administration said on Thursday it has asked Endo International to withdraw from the market its long-lasting opioid painkiller Opana ER, sending the company’s shares down as much as 13%. “After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer…

IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk

Reuters Staff | June 8, 2017

NEW YORK (Reuters Health)—Immunosuppressants and anti-TNF drugs do not appear to increase the risk of extracolonic cancers in patients with inflammatory bowel disease (IBD), researchers from Spain report. IBD patients face an increased risk of colon cancer, and some studies have suggested there might be an increased risk of extracolonic cancer. Dr. Maria Chaparro from…